Nomura Asset Management CO LTD Mirati Therapeutics, Inc. Transaction History

Nomura Asset Management CO LTD

20 transactions

Quarter	Operation	Price Per share
Q3 2022 Nov 14, 2022	BUY	$59.5 - $86.7 $0 - $0
Q3 2022 Nov 10, 2022	BUY	$59.5 - $86.7 $0 - $0
Q3 2022 Nov 10, 2022	BUY	$59.5 - $86.7 $0 - $0
Q2 2022 Aug 12, 2022	BUY	$39.16 - $88.71 $0 - $0
Q1 2022 May 13, 2022	BUY	$75.82 - $150.97 $0 - $0
Q4 2021 Feb 01, 2022	BUY	$132.01 - $190.29 $0 - $0
Q3 2021 Nov 12, 2021	BUY	$132.13 - $177.45 $0 - $0
Q2 2021 Aug 06, 2021	BUY	$144.0 - $179.73 $0 - $0
Q1 2021 May 14, 2021	BUY	$158.92 - $221.61 $0 - $0
Q4 2020 Feb 12, 2021	BUY	$162.05 - $240.27 $0 - $0
Q3 2020 Nov 12, 2020	BUY	$113.26 - $167.27 $0 - $0
Q2 2020 Aug 13, 2020	BUY	$72.01 - $120.39 $0 - $0
Q1 2020 May 14, 2020	BUY	$69.78 - $116.21 $0 - $0
Q4 2019 Feb 13, 2020	BUY	$70.76 - $128.86 $0 - $0
Q3 2019 Nov 13, 2019	BUY	$77.91 - $109.6 $0 - $0
Q2 2019 Aug 13, 2019	BUY	$59.49 - $104.71 $0 - $0
Q1 2019 May 10, 2019	BUY	$43.65 - $78.95 $0 - $0
Q1 2019 May 10, 2019	BUY	$43.65 - $78.95 $0 - $0
Q4 2018 Feb 12, 2019	BUY	$32.0 - $47.43 $0 - $0
Q3 2018 Nov 07, 2018	BUY	$47.1 - $62.7 $0 - $0

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Nomura Asset Management CO LTD, based on Form 13F filings with the SEC.

Stay updated on Nomura Asset Management CO LTD with notifications on news.